# US 2021/0277150 A1 · STABLE HETERODIMERIC ANTIBODY DESIGN WITH MUTATIONS IN THE Fc DOMAIN

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0277150 A1
- Document ID: US20210277150A1
- Status: Published application
- Kind: A1
- Application number: 17/107,217
- Filed: 2020-11-30
- Published: 2021-09-09
- Earliest claimed: 2010-11-05
- Assignees: Zymeworks Inc.
- Applicants: Zymeworks Inc.
- Inventors: Thomas Spreter Von Kreudenstein; Eric Escobar-Cabrera; Surjit Bhimarao Dixit; Paula Irene Lario; David Kai Yuen Poon; Igor D'Angelo
- Web page: https://patentgrep.com/patent/US20210277150A1

## CPC

- C07K 16/468: {Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies}
- A61P 35/00: Antineoplastic agents
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07K 16/00: Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K 16/32: against translation products of oncogenes
- C07K 2317/30: characterized by aspects of specificity or valency
- C07K 2317/524: CH2 domain
- C07K 2317/526: CH3 domain
- C07K 2317/64: comprising a combination of variable region and constant region components
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The provided scaffolds have heavy chains that are asymmetric in the various domains (e.g. CH2 and CH3) to accomplish selectivity between the various Fc receptors involved in modulating effector function, beyond those achievable with a natural homodimeric (symmetric) Fc molecule, and increased stability and purity of the resulting variant Fc heterodimers. These novel molecules comprise complexes of heterogeneous components designed to alter the natural way antibodies behave and that find use in therapeutics.

## Claims

### Claim 1

(canceled)

### Claim 2

An isolated heteromultimer comprising a heterodimer Fc region, wherein the heterodimer Fc region comprises a first Fc polypeptide and a second Fc polypeptide and a variant CH3 domain comprising amino acid modifications to promote heterodimer formation, wherein:
(i) the first Fc polypeptide comprises amino acid modifications at positions F405 and Y407, wherein the amino acid modification at position F405 is F405A, F405S, F405T or F405V, and the amino acid modification at position Y407 is Y407A, Y407I, Y407L or Y407V, and
(ii) the second Fc polypeptide comprises amino acid modifications at positions T366 and T394, wherein the amino acid modification at position T366 is T366I, T366L, T366M or T366V, and the amino acid modification at position T394 is T394W,
wherein the heterodimer Fc region further comprises a variant CH2 domain comprising asymmetric amino acid modifications to promote selective binding of a Fcgamma receptor,
wherein the heterodimer Fc region is based on an IgG Fc region,
and wherein the numbering of amino acid residues is according to the EU index as set forth in Kabat.

### Claim 3 (depends on 2)

The isolated heteromultimer according to claim 2, wherein the variant CH2 domain selectively binds FcgammaIIIa receptor as compared to a wild-type CH2 domain.

### Claim 4 (depends on 2)

The isolated heteromultimer according to claim 2, wherein the variant CH3 domain has a melting temperature (Tm) of about 70° C. or greater.

### Claim at position 5

-7. (canceled)

### Claim 8 (depends on 2)

The isolated heteromultimer according to claim 2, wherein the heterodimer Fc region has a purity greater than about 90%.

### Claim 9 (depends on 2)

The isolated heteromultimer according to claim 2, wherein the heterodimer Fc region has a purity of about 95% or greater.

### Claim at position 8

-11. (canceled)

### Claim 12 (depends on 2)

The isolated heteromultimer according to claim 2, wherein the variant CH3 domain has a Tm of about 74° C. or greater.

### Claim at position 10

-34. (canceled)

### Claim 35 (depends on 2)

The isolated heteromultimer according to claim 2, wherein the amino acid modification at position F405 is F405A.

### Claim 36 (depends on 2)

The isolated heteromultimer according to claim 2, wherein the second Fc polypeptide further comprises an amino acid modification at position K392, and wherein the amino acid modification at position K392 is K392V, K392M, K392L or K392F.

### Claim at position 13

-40. (canceled)

### Claim 41 (depends on 2)

The isolated heteromultimer according to claim 2, wherein the first Fc polypeptide further comprises the amino acid modification L351Y.

### Claim 42 (depends on 2)

The isolated heteromultimer according to claim 2, wherein the amino acid modification at position T366 is T366L or T366I.

### Claim 43 (depends on 2)

The isolated heteromultimer according to claim 2, wherein the amino acid modification at position Y407 is Y407V.

### Claim 44

(canceled)

### Claim 45 (depends on 2)

The isolated heteromultimer according to claim 2, wherein the first Fc polypeptide comprises the amino acid modifications F405A and Y407V, and the second Fc polypeptide comprises the amino acid modifications T366L and T394W.

### Claim 46 (depends on 2)

The isolated heteromultimer according to claim 2, wherein the first Fc polypeptide comprises the amino acid modifications F405A and Y407V, and the second Fc polypeptide comprises the amino acid modifications T366I and T394W.

### Claim at position 20

-53. (canceled)

### Claim 54 (depends on 2)

The isolated heteromultimer according to claim 2, wherein the first Fc polypeptide further comprises an amino acid modification at position S400, wherein the amino acid modification at position S400 is S400E or S400D.

### Claim 55

(canceled)

### Claim 56 (depends on 2)

The isolated heteromultimer according to claim 2, wherein the second Fc polypeptide further comprises the amino acid modification N390R.

### Claim 57 (depends on 2)

The isolated heteromultimer according to claim 2, wherein the second Fc polypeptide further comprises an amino acid modification at position K392 selected from K392M and K392L.

### Claim at position 25

-77. (canceled)

### Claim 78 (depends on 57)

The isolated heteromultimer according to claim 57, wherein the first Fc polypeptide comprises the amino acid modifications F405A and Y407V and the second Fc polypeptide comprises the amino acid modifications T366I, K392M and T394W.

### Claim 79 (depends on 57)

The isolated heteromultimer according to claim 57, wherein the first Fc polypeptide comprises the amino acid modifications F405A and Y407V and the second Fc polypeptide comprises the amino acid modifications T366L, K392M and T394W.

### Claim 80 (depends on 57)

The isolated heteromultimer according to claim 57, wherein the first Fc polypeptide comprises the amino acid modifications F405A and Y407V and the second Fc polypeptide comprises the amino acid modifications T366L, K392L and T394W.

### Claim 81 (depends on 57)

The isolated heteromultimer according to claim 57, wherein the first Fc polypeptide comprises the amino acid modifications F405A and Y407V and the second Fc polypeptide comprises the amino acid modifications T366I, K392L and T394W.

### Claim 82 (depends on 2)

The isolated heteromultimer according to claim 2, wherein the heteromultimer is a bispecific antibody.

### Claim 83 (depends on 2)

The isolated heteromultimer according to claim 2, wherein the heteromultimer is a multispecific antibody.

### Claim 84 (depends on 2)

A composition comprising the isolated heteromultimer according to claim 2, and a pharmaceutically acceptable carrier.

### Claim 85 (depends on 2)

A host cell comprising nucleic acid encoding the isolated heteromultimer according to claim 2.

### Claim 86 (depends on 2)

The isolated heteromultimer according claim 2, wherein the heteromultimer is a therapeutic antibody.

### Claim 87

(canceled)

### Claim 88 (depends on 86)

A method of treating cancer in a patient having a cancer characterized by a cancer antigen, said method comprising administering to said patient a therapeutically effective amount of a heteromultimer of claim 86.

### Claim 89 (depends on 86)

A method of treating immune disorders in a patient having an immune disorder characterized by an immune antigen, said method comprising administering to said patient a therapeutically effective amount of a heteromultimer of claim 86.

### Claim 90

(canceled)

### Claim 91 (depends on 2)

Nucleic acid encoding the isolated heteromultimer according to claim 2.

### Claim 92 (depends on 2)

The isolated heteromultimer according to claim 2, wherein:
(a) the first Fc polypeptide comprises the amino acid modifications L351Y, F405A and Y407V and the second Fc polypeptide comprises the amino acid modifications T366L, K392L and T394W;
(b) the first Fc polypeptide comprises the amino acid modifications L351Y, F405A and Y407V and the second Fc polypeptide comprises the amino acid modifications T366L, K392M and T394W, or
(c) the first Fc polypeptide comprises the amino acid modifications L351Y, S400E, F405A and Y407V and the second Fc polypeptide comprises the amino acid modifications T366L, N390R, K392M and T394W.

### Claim 93 (depends on 2)

The isolated heteromultimer according to claim 2, wherein the variant CH2 domain comprises one or more asymmetric amino acid modifications selected from: S239D, D265S, S267D, E269K, S298A, K326E, A330L and I332E.

### Claim 94 (depends on 93)

The isolated heteromultimer according to claim 93, wherein the one or more asymmetric amino acid modifications are selected from: S239D, K326E, A330L and I332E.

### Claim 95 (depends on 93)

The isolated heteromultimer according to claim 93, wherein the one or more asymmetric amino acid modifications are selected from: S239D, D265S, E269K and I332E.

### Claim 96 (depends on 93)

The isolated heteromultimer according to claim 93, wherein the one or more asymmetric amino acid modifications are selected from: S239D, D265S and S298A.

### Claim 97 (depends on 93)

The isolated heteromultimer according to claim 93, wherein the one or more asymmetric amino acid modifications are selected from: S239D, S298A, K326E, A330L and I332E.

### Claim 98 (depends on 93)

The isolated heteromultimer according to claim 93, wherein the one or more asymmetric amino acid modifications are selected from: S239D, D265S, S298A and I332E.

### Claim 99 (depends on 2)

The isolated heteromultimer according to claim 2, wherein the heterodimer Fc region is based on an IgG1 Fc region.

### Claim 100 (depends on 2)

The isolated heteromultimer according to claim 2, wherein the heterodimer Fc region is based on a human IgG1 Fc region.
